

## A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK)

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** Up to 18 years old

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

1. Child 1 to 18 years old 2. Diagnosed by biopsy with specific types of glomerular disease & protein in the urine 3. Blood pressure is within normal range for age 4. Maintained on a stable dose of immunosuppressive medications

---

#### Exclusion Criteria:

1. Weight less than 7.3 kg (16 pounds) at screening. 2. Disease due to viral infections, drug toxicities, or cancer. 3. Kidney function is below the minimum required

### Conditions & Interventions

#### Interventions:

Drug: Sparsentan, Drug: Sparsentan, Drug: Sparsentan

#### Conditions:

Children's Health, Kidney, Prostate & Urinary, Rare Diseases

#### Keywords:

Alport Syndrome, Glomerulosclerosis, IgA Vasculitis, Immunoglobulin A Nephropathy

### More Information

**Description:** Currently, there are no approved treatment options for pediatric subjects with proteinuric kidney conditions. The study will look at the safety, efficacy, and pharmacokinetic (PK) trial in children  $\geq 1$  to  $<18$  years treated for up to 108 weeks with the drug sparsentan.

**Study Contact:** Amy Hanson - amhanson@umn.edu

**Principal Investigator:** Michelle Rheault

#### IRB

**Number:** SITE00001245

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.